ADC Therapeutics SA

Equities

ADCT

CH0499880968

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:59:39 2024-04-25 pm EDT			5-day change	1st Jan Change
4.45 ^USD	-6.90%		-4.62%	+173.49%

Apr. 09	Transcript : ADC Therapeutics SA - Special Call
Apr. 04	Sector Update: Health Care Stocks Slump Late Afternoon	MT

ADC Therapeutics, Swedish Orphan Biovitrum's Co-Developed Drug Recommended for EU Authorization

September 16, 2022 at 06:11 am EDT

By Sabela Ojea

ADC Therapeutics SA and Swedish Orphan Biovitrum said Friday that a European Medicines Agency committee has recommended granting marketing authorization for their co-developed Zynlonta drug, aimed at treating patients with diffuse large b-cell lymphomas in Europe.

The companies said that the European Union's Committee for Medicinal Products for Human Use has a positive opinion on the treatment of this type of cancer, which begins in the lymphatic system.

The positive opinion from the CHMP is now referred to the European Commission for an approval decision, the companies said.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

09-16-22 0811ET

Latest news about ADC Therapeutics SA

Transcript : ADC Therapeutics SA - Special Call	Apr. 09
Sector Update: Health Care Stocks Slump Late Afternoon	Apr. 04	MT
ADC Therapeutics Shares Rise After Completion of Dose Escalation Part of Phase 1b Lymphoma Trial	Apr. 04	MT
Chiome Bioscience Cancels License Agreements with ADC Therapeutics	Mar. 31	MT
Guggenheim Initiates ADC Therapeutics With Buy Rating, $11 Price Target	Mar. 28	MT
Transcript : ADC Therapeutics SA, Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
ADC Therapeutics SA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
ADC Therapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
RBC Lifts Price Target on ADC Therapeutics to $8 From $6, 'Encouraged' by Competitive Positioning; Outperform, Speculative Risk Kept	Feb. 26	MT
HC Wainwright Raises Price Target on ADC Therapeutics to $9 From $3, Maintains Buy Rating	Feb. 20	MT
Certain Common Shares of ADC Therapeutics SA are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	Feb. 02	CI
Certain Restricted Stock Units of ADC Therapeutics SA are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	Feb. 02	CI
Certain Warrants of ADC Therapeutics SA are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	Feb. 02	CI
Certain Options of ADC Therapeutics SA are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	Feb. 02	CI
ADC Therapeutics SA Enters First Amendment to the Loan Agreement	Jan. 19	CI
ADC Therapeutics Regains Compliance With NYSE Continued Listing Standards	Jan. 04	MT
HC Wainwright Adjusts Price Target on ADC Therapeutics to $3 From $12, Keeps Buy Rating	Nov. 20	MT
TD Cowen Downgrades ADC Therapeutics to Market Perform From Outperform	Nov. 09	MT
RBC Cuts Price Target on ADC Therapeutics to $6 From $7, Keeps Outperform, Speculative Risk	Nov. 08	MT
Transcript : ADC Therapeutics SA, Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
ADC Therapeutics SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
RBC Trims Price Target on ADC Therapeutics to $8 From $9 Amid Guidance Withdrawal, Keeps Outperform, Speculative Risk	23-09-12	MT
Transcript : ADC Therapeutics SA Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 02:15 PM	23-09-11
ADC Therapeutics SA Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs At the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)	23-08-30	CI
JPMorgan Upgrades ADC Therapeutics to Neutral From Underweight	23-08-10	MT

Chart ADC Therapeutics SA

Duration

Period

More charts

Company Profile

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkinâs lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for ADC Therapeutics SA

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.78 USD

Average target price

10.2 USD

Spread / Average Target

+113.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADC THERAPEUTICS SA	+173.49%	394M
VERTEX PHARMACEUTICALS INCORPORATED	-1.90%	104B
REGENERON PHARMACEUTICALS, INC.	+2.00%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.60%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-16.17%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+3.89%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.77%	11.66B

Bio Therapeutic Drugs